Liquidia (FRA:LT4) Cash And Cash Equivalents : €157.03 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Liquidia Cash And Cash Equivalents?

Liquidia's quarterly cash and cash equivalents declined from Sep. 2024 (€184.14 Mil) to Dec. 2024 (€168.54 Mil) but then stayed the same from Dec. 2024 (€168.54 Mil) to Mar. 2025 (€157.03 Mil).

Liquidia's annual cash and cash equivalents declined from Dec. 2022 (€88.06 Mil) to Dec. 2023 (€76.73 Mil) but then increased from Dec. 2023 (€76.73 Mil) to Dec. 2024 (€168.54 Mil).

Liquidia Cash And Cash Equivalents Historical Data

The historical data trend for Liquidia's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia Cash And Cash Equivalents Chart

Liquidia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

53.69

50.88

88.06

76.73

168.54

Liquidia Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															145.23	123.64	184.14	168.54	157.03

Liquidia Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Liquidia (FRA:LT4) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Liquidia Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Liquidia's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Liquidia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (FRA:LT4) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

LQDA:USA

Address

419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560

Website

https://www.liquidia.com

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Headlines

No Headlines